# Can-Fite BioPharma clinical trials: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Can-Fite BioPharma as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Can-Fite BioPharma: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/can-fite-biopharma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 13, 2026 | NCT07410455 | An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome | Can-Fite BioPharma | Phase 2 | Not yet recruiting | Lowe Syndrome | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410455) |
| October 16, 2024 | NCT06643260 | A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy | Can-Fite BioPharma | Phase 3 | Not yet recruiting | Plaque Psoriasis | 705 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06643260) |
| April 29, 2024 | NCT06387342 | Namodenoson Treatment of Advanced Pancreatic Cancer | Can-Fite BioPharma | Phase 2 | Recruiting | Pancreatic Adenocarcinoma, Pancreatic Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06387342) |
| January 21, 2022 | NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis | Can-Fite BioPharma | Phase 3 | Recruiting | Hepatocellular Carcinoma, Cirrhosis | 471 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05201404) |
| January 6, 2021 | NCT04697810 | Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) | Can-Fite BioPharma | Phase 2 | Unknown | NASH - Nonalcoholic Steatohepatitis | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04697810) |
| April 3, 2020 | NCT04333472 | Piclidenoson for Treatment of COVID-19 | Can-Fite BioPharma | Phase 2 | Completed | COVID-19, Coronavirus Infection | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04333472) |
| May 30, 2017 | NCT03168256 | CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis | Can-Fite BioPharma | Phase 3 | Completed | Plaque Psoriasis | 528 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03168256) |
| October 7, 2016 | NCT02927314 | A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease | Can-Fite BioPharma | Phase 2 | Completed | Non-alcoholic Steatohepatitis (NASH) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02927314) |
| January 6, 2016 | NCT02647762 | CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis | Can-Fite BioPharma | Phase 3 | Terminated | Rheumatoid Arthritis | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02647762) |
| May 1, 2014 | NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | Can-Fite BioPharma | Phase 2 | Completed | Hepatocellular Carcinoma | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02128958) |
| July 23, 2013 | NCT01905124 | Safety &Efficacy of CF101 to Subjects With Uveitis | Can-Fite BioPharma | Phase 2 | Withdrawn | Uveitis, Posterior, Uveitis, Intermediate | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01905124) |
| December 23, 2010 | NCT01265667 | Trial of CF101 to Treat Patients With Psoriasis | Can-Fite BioPharma | Phase 2/3 | Completed | Plaque Psoriasis | 293 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01265667) |
| November 5, 2010 | NCT01235234 | Trial of CF101 to Treat Patients With Dry Eye Disease | Can-Fite BioPharma | Phase 3 | Completed | Keratoconjunctivitis Sicca | 236 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01235234) |
| December 17, 2009 | NCT01034306 | Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis | Can-Fite BioPharma | Phase 2 | Completed | Rheumatoid Arthritis | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01034306) |
| December 16, 2009 | NCT01033422 | Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure | Can-Fite BioPharma | Phase 2 | Completed | Ocular Hypertension, Glaucoma | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01033422) |
| February 5, 2009 | NCT00837291 | A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee | Can-Fite BioPharma | Phase 2 | Withdrawn | Osteoarthritis of the Knee | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00837291) |
| November 13, 2008 | NCT00790673 | A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 | Can-Fite BioPharma | Phase 1/2 | Completed | Chronic Hepatitis C | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00790673) |
| November 13, 2008 | NCT00790218 | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma | Can-Fite BioPharma | Phase 1/2 | Completed | Hepatocellular Carcinoma | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00790218) |
| November 12, 2007 | NCT00556894 | Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients | Can-Fite BioPharma | Phase 2 | Completed | Rheumatoid Arthritis | 253 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00556894) |
| January 30, 2007 | NCT00428974 | Safety and Efficacy Study of CF101 to Treat Psoriasis | Can-Fite BioPharma | Phase 2 | Completed | Plaque Psoriasis | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00428974) |
| July 7, 2006 | NCT00349466 | Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca | Can-Fite BioPharma | Phase 2 | Completed | Keratoconjunctivitis Sicca | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00349466) |
| January 24, 2006 | NCT00280917 | Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients | Can-Fite BioPharma | Phase 2 | Completed | Rheumatoid Arthritis | 254 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00280917) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1/2 | 2 |
| Phase 2 | 14 |
| Phase 2/3 | 1 |
| Phase 3 | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 14 |
| Recruiting | 2 |
| Withdrawn | 2 |
| Not yet recruiting | 2 |
| Unknown | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Arthritis, Rheumatoid | 4 |
| Carcinoma, Hepatocellular | 3 |
| Psoriasis | 3 |
| Keratoconjunctivitis Sicca | 2 |
| Dry Eye Syndromes | 2 |
| Non-alcoholic Fatty Liver Disease | 2 |
| Ocular Hypertension | 1 |
| Glaucoma | 1 |
| Pancreatic Neoplasms | 1 |
| Osteoarthritis, Knee | 1 |
| Osteoarthritis | 1 |
| Uveitis, Posterior | 1 |
| Uveitis, Intermediate | 1 |
| Uveitis | 1 |
| COVID-19 | 1 |
| Coronavirus Infections | 1 |
| Hepatitis C, Chronic | 1 |
| Hepatitis C | 1 |
| Fibrosis | 1 |
| Liver Neoplasms | 1 |
| Oculocerebrorenal Syndrome | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Automation companies in the United States](https://specstream.ai/data/businesses/automation-companies/united-states)
- [Security companies in the United States](https://specstream.ai/data/businesses/security-companies/united-states)
- [Manufacturers in the United States](https://specstream.ai/data/businesses/manufacturers/united-states)
- [Entertainment law firms in the United States](https://specstream.ai/data/businesses/entertainment-law-firms/united-states)
- [B2B telemarketing companies in the United States](https://specstream.ai/data/businesses/b2b-telemarketing-companies/united-states)
- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
